Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ENSEMBLE

- PMLiVE

Cambridge study reveals potential biomarker and target for long COVID treatments

The pro-inflammatory molecule, IFN-Y, persisted until symptoms improved in patients

- PMLiVE

Johnson & Johnson’s Tecvayli receives FDA approval for reduced dosing in multiple myeloma patients

More than 35,000 cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

Study reveals T cells could provide more protection against Omicron in future vaccines

Memory T cells were found to be more effective at fighting SARS-CoV-2 than antibodies

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine available to buy in UK following MHRA endorsement

The XBB.1.5-adapted vaccine will be available for purchase from March 2024

- PMLiVE

Johnson & Johnson and Protagonist’s JNJ-2113 shows promise in plaque psoriasis

The immune-mediated disease is estimated to affect more than 125 million people worldwide

- PMLiVE

Johnson & Johnson’s nipocalimab shows promise in autoimmune disorder studies

The drug is currently being evaluated in patients with gMG and Sjögren’s disease

- PMLiVE

DNA-based vaccine induces strong antibody response against SARS-CoV-2

The DNA scaffold carries multiple copies of a viral antigen which mimics virus structures

- PMLiVE

Novavax’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

Individuals in the UK aged 12 years and older will be eligible to receive Nuvaxovid XBB.1.5

- PMLiVE

Johnson & Johnson agrees $700m settlement to resolve talcum powder investigations

The deal would resolve US states’ probes into the marketing of its talcum products

- PMLiVE

Study finds vaccination against COVID-19 reduces long COVID symptoms

The results could help inform public health strategies and vaccination campaigns

- PMLiVE

Johnson & Johnson’s bladder cancer drug Balversa granted full FDA approval

Urothelial carcinoma accounts for approximately 90% of bladder cancer cases

- PMLiVE

Pfizer’s COVID-19 antiviral Paxlovid recommended by NICE for expanded use

The latest guidance will mean an estimated 5.3 million people will be eligible to access Paxlovid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links